-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Events
Latest From Events
Orphan Drugs: Making Rare Diseases Rarer
A panel at the BIO CEO & Investor Conference provided an analysis of the thriving orphan drug market opportunity featuring industry, clinical and regulatory experts specializing in rare diseases. The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the Read More >
Small Biotech Companies and China: 5 Keys to Success
Big pharmaceutical countries aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China’s lucrative market and maximize their investment in the country. With limited resources, how can smaller companies operate efficiently and give Chinese patients access to their innovative products? A panel of experts explored these questions at the 2013 BIO CEO & Investor Conference. Jimmy Zhang from Merck moderated a panel including: Friedhelm Blobel, PhD, President, CEO, Read More >
Despite Low Funding, Biotech Productivity Remains High In 2013
At the 2013 BIO CEO & Investor Conference, John Milligan, President and COO of Gilead Sciences, spoke in a standing room only fireside chat with Joel Sendek, Managing Director of Stifel Nicolaus, who moderated the discussion. Nicolaus noted that Gilead’s market cap has grown at an astounding 40 fold over the past 15 years, and asked Milligan to speak about the current state of the biotech industry. Milligan explained that biotech is not becoming more Read More >
Tracks & Attendees Put the “International” in the BIO International Convention
As the BIO International Convention celebrates its 20th year, there is no time like the present to reflect on the evolution of the world’s largest biotechnology industry gathering, and what it illustrates in terms of the patterns of global industry achievements. Overall attendance growth over the years – from a 4,000-strong audience in 1998 to an audience topping 16,000 in 2012 – provides a clear indication of how far this industry has come towards developing and Read More >
Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech
After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most Influential People in Bipoharma Today,” N. Anthony (Tony) Coles, MD, Chairman & CEO of Onyx Pharmaceuticals sat down with Steve Usdin, Senior Editor of BioCentury for an early morning Fireside Chat at the 15th Annual BIO CEO & Investor Conference. To read more about Onyx’s stellar year and their company milestones, visit here. The biotech retained complete control in the Read More >
